Bilypsa Tablet
Marketer
Zydus Cadila
Salt Composition
Saroglitazar (4mg)
Overview Bilypsa Tablet
Odysseo tablets treat non-cirrhotic, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease (NAFLD) accompanied by conditions such as obesity, type 2 diabetes, high cholesterol (diabetic dyslipidemia), or metabolic syndrome. For optimal results, take Odysseo daily at the same time, with or without food, and continue until your physician advises otherwise. Maintaining your prescribed diet and exercise regimen is crucial; lifestyle changes significantly contribute to healthy weight management and liver protection. Common, usually mild, side effects include gas, indigestion, abdominal bloating, fever, and fatigue. Report any persistent or concerning side effects to your doctor. Inform your doctor of any history of kidney, heart, or pancreatic issues, excessive alcohol consumption, or pregnancy/breastfeeding before starting Odysseo. Disclose all other medications you are taking, as interactions are possible. Reduce alcohol intake while using this medication to safeguard liver health. Regular monitoring of liver and kidney function, as well as blood sugar, may be necessary to assess treatment effectiveness.
Primary Ingredients of Bilypsa Tablet
The provided text is "undefined," which offers no content to rephrase. Therefore, no rewritten text can be provided.
Uses of Bilypsa Tablet
Managing Nonalcoholic Steatohepatitis (NASH) without cirrhosis | Addressing Nonalcoholic Fatty Liver Disease (NAFLD) | Diabetic Lipid Management (hyperlipidemia in diabetes)
Major Benefits of Bilypsa Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the tablet whole; do not chew, crush, or fracture it. Bilypsa Tablets can be administered with or without food, though consistent timing is recommended.
Common Side effects of Bilypsa Tablet:
- Flatulence
- Indigestion
- Abdominal distension
- Weakness
- Increased body temperature
How to use Bilypsa Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the tablet whole; avoid crushing, chewing, or breaking it. Bilypsa Tablets can be administered with or without food, although consistent timing is recommended.
How Bilypsa Tablet works:
Saroglitazar, the active ingredient in Bilypsa tablets, is a dual peroxisome proliferator-activated receptor (PPAR) antagonist. This medication helps control elevated cholesterol, particularly triglyceride levels, and blood glucose in patients with type 2 diabetes. Bilypsa achieves this through a novel mechanism, suppressing triglyceride production and release (a specific type of blood lipid). Furthermore, it enhances insulin sensitivity, optimizing glucose metabolism and subsequently reducing blood sugar.
SAFETY ADVICE
AlcoholUNSAFE
Consuming alcohol while taking Bilypsa Tablet is inadvisable.
PregnancyCONSULT YOUR DOCTOR
Using Bilypsa tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the potential benefits against any risks prior to prescription. Seek medical advice.
Breast feedingCAUTION
The use of Bilypsa Tablets while breastfeeding requires careful consideration. Mothers should discontinue breastfeeding for the duration of their treatment and until the medication is fully cleared from their system.
DrivingSAFE
Driving ability is typically unaffected by Bilypsa Tablet.
KidneyCONSULT YOUR DOCTOR
Insufficient data exists regarding Bilypsa Tablet use in patients exhibiting renal impairment. Physician consultation is recommended.
LiverCONSULT YOUR DOCTOR
Insufficient data exists regarding Bilypsa Tablet use in individuals with hepatic impairment. Physician consultation is advised.
What if you forget to take Bilypsa Tablet :
Omit a dose? Take it immediately if you remember. However, if your next dose is imminent, forgo the missed one and proceed with your regular schedule. Never take a double dose.
Facts to Know About Bilypsa Tablet
| Label | Value |
|---|---|
| Chemical Type | Pyrrole-phenyl derivative |
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
| Behavior Class | PPARα/γ dual agonist |





